NCT03130946

Brief Summary

Axillary lymph node status is a vital prognostic factor in breast cancer patients and provides crucial information for making treatment decisions. Ultrasound test with subsequent fine needle aspiration (FNA) biopsy in nodes with suspicious features remains the standard of axillary lymph node workup. Insufficient sampling and limited diagnostic accuracy of cytological test compromise the outcome the preoperative lymph node staging strategy especially in patients with intermediate suspicious nodes. This prospective study is to compare the performance of a crpo-assisted core biopsy with FNA.

Trial Health

33
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Trial recruitment is currently suspended
Enrollment
135

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started May 2017

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
suspended

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 23, 2017

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 27, 2017

Completed
4 days until next milestone

Study Start

First participant enrolled

May 1, 2017

Completed
5.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2022

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2023

Completed
Last Updated

October 18, 2022

Status Verified

October 1, 2022

Enrollment Period

5.6 years

First QC Date

April 23, 2017

Last Update Submit

October 14, 2022

Conditions

Keywords

breast neoplasmsUltrasonography, InterventionalBiopsy, Large-Core NeedleBiopsy, Fine-Needle

Outcome Measures

Primary Outcomes (1)

  • Sensitivity of biopsy

    True positive rate measures the proportion of positives that are correctly identified by Core needle or FNA

    Immediate after pathological lymph node stage is available

Secondary Outcomes (3)

  • Specificity

    Immediate after pathological lymph node stage is available.

  • Sample adequency

    Immediate after biopsy specimen is evaluated by pathologists.

  • Adverse effect of surgery

    4 weeks after surgery.

Study Arms (2)

Cryo-assisted core needle biopsy

EXPERIMENTAL

Eligible patients undergo lymph node biopsy with FNA and crpo-assisted stick freeze device sequentially.

Device: Cryo-assisted core needle biopsyDevice: FNA

Fine needle aspiration alone

ACTIVE COMPARATOR

Patients undergo lymph node biopsy with FNA alone.

Device: FNA

Interventions

Rotational core needle biopsy would be done under local anesthesia. A small incision would be made in the axilla and core needle biopsy be performed using a special cryo-assisted stick freeze device (Cassi II, Scion Medical Technologies, USA). The cytological and histological specimens would be sent for diagnosis.

Cryo-assisted core needle biopsy
FNADEVICE

FNA would be performed using a 10ml syringe with a 24 gauge needle without anesthesia.

Cryo-assisted core needle biopsyFine needle aspiration alone

Eligibility Criteria

Age18 Years - 70 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Histologically confirmed invasive breast cancer.
  • With axillary lymph node with thickened cortex.
  • Planned for sentinel lymph node biopsy or axillary clearance.

You may not qualify if:

  • Nodes ultrasonographically normal.
  • Nodes with hilar displacement .
  • Palpable matted nodes.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Peking University People's Hospital

Beijing, Beijing Municipality, 10044, China

Location

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Shu Wang, MD

    Peking University People's Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Model Details: Two arm, prospective, open label study
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

April 23, 2017

First Posted

April 27, 2017

Study Start

May 1, 2017

Primary Completion

December 1, 2022

Study Completion

December 1, 2023

Last Updated

October 18, 2022

Record last verified: 2022-10

Locations